Home - About Us
About

BioSynchronicity Corporation

BioSynchronicity Corporation is an SBA certified Woman Owned Small Business (WOSB) launched in June 2020 in the State of Washington. The focus of the BioSynchronicity team is the design, development, research, validation, manufacturing, and commercialization of in vitro, clinical diagnostic, and forensic tests and devices for the health of humans, animals, and the ecosystem.

At the time of its launch, BioSynchronicity was tasked with designing and developing a reliable, simple, affordable, widely-available, and ultra-rapid SARS-CoV-2 antigen diagnostic test for hospital and point of care (POC) use, school and business screening programs, as well as self-administed testing at home through over-the-counter (OTC) sales where authorized by regulatory bodies.

To meet this challenge, a global team of like-minded scientists, doctors, engineers, and other seasoned international business professionals was assembled, resulting in the creation of our first test: the C-Sync® COVID-19 Antigen Test, a multi-target test to detect SARS-CoV-2. The C-Sync® COVID-19 Antigen Test received an EUA in March 2023. Our team has leveraged our innovative C-Sync® platform to develop new diagnostic tests.

BioSynchronicity has received an Emergency Use Authorization from the FDA (EUA220346) for its flagship lateral flow assay (LFA), the C-Sync® COVID-19 Antigen Test. The C-Sync® assay platform is readily adaptable to the detection of a broad spectrum of viral and bacterial infections. Highly accurate and sensitive rapid forensic singleplex and multiplex tests for the detection of Fentanyl, Xylazine, and other opioids and illicit drugs are available for Harm Reduction programs, as well as for employee drug screening and insurance testing. Test device customization, private label, and OEM options are available.

A new series of innovative diagnostic tests dedicated to improve women’s and neonatal health are also in development.

Trust & Partnership

BioSynchronicity is not a commodity company. We are a science-based solution company. We intend to earn your trust by providing rapid antigen tests that are fast, reliable, affordable, and available. Our commitment is to help people, companies, schools, event venues, hospitals, restaurants, and places that need quick health status results. This includes affluent and under-served communities alike, and both developed and developing areas around the world.

While the C-Sync® platform can be used now for COVID-19, it may be leveraged to test for other current and future critical medical needs, such as seasonal influenza, measles, mumps, tuberculosis, pneumonia, syphilis, HIV, diabetes, and the detection of restricted drugs such as opioids.

As we continue to build trust with our C-Sync® tests, we look forward to expand our business relationships with new innovative products and services in the future.

BioSynchronicity Viral Diagnostic Tests

BioSynchronicity is focused on point-of-care (POC) testing (i.e. testing in the field rather than a laboratory) and home self-testing where authorized by local regulatory bodies. Scientists generally agree that a frequent and consistent regimen of POC testing is essential to fight the spread of highly contagious viruses, as it allows rapid identification of infected patients to enable isolation and efficient contact tracing. Although point-of-care RT-PCR diagnostics exist, they have been superseded by tests that use more rapid amplification technologies (e.g., LAMP) and smaller instruments. New high sensitivity Lateral Flow Assays from BioSynchronicity using a simple nasal sample continue to gain trust from health professionals. In development are systems which will use a saliva sample as a biological specimen, offering significant advantages over traditional diagnostic testing for viruses, pathogens, bacteria, and toxic substances. They are affordable, accurate, do not require trained technicians, do not require additional laboratory equipment, and are easy to use with easily interpreted rapid results in minutes.